HepaLife's Liver Stem Cell Line Launched Onboard NASA's Space Shuttle Endeavour Mission STS-126 For Special Experiments During 15-day Roundtrip

Main Category: Liver Disease / Hepatitis
Also Included In: Stem Cell Research;  Biology / Biochemistry
Article Date: 18 Nov 2008 - 10:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing the first-of-its-kind bioartificial liver device intended for the treatment of liver failure, announced today that its proprietary 'PICM-19' liver stem cell line is onboard the Space Shuttle "Endeavour" as part of a scientific experiment to investigate the differentiation and function of stem cells in space. The research is being performed under the International Space Station National Laboratory initiative.

"We are honored that America's space program has selected HepaLife's liver cells to be part of this important space mission. This event is testimony to the outstanding liver-like functionality of these cells and supports our long-held conviction that our patented PICM-19 cell line is a one-of-a-kind cellular model," stated Mr. Frank Menzler, President, CEO and Chairman of HepaLife Technologies, Inc.

In addition to serving as a model for stem cell differentiation and function, HepaLife's PICM cell line is particularly suitable for assessing the effects of space flight and microgravity and on the ability of the human liver to regenerate, a normal but crucial attribute of the liver.

HepaLife's PICM-19 cell line is the only stem cell known to successfully differentiate into either bile duct cells or hepatocytes, the two cell types that make up 98% of the liver's tissues and perform the vital functions of the liver. As such, the PICM-19 cells are an ideal in-vitro liver model for either hepatocyte differentiation and function, or bile duct differentiation and function -- the primary role of the cells in experiments aboard the Space Shuttle Endeavour, launched late last week.

Endeavour was successfully launched on Friday, November 14, with the International Space Station as its destination. The shuttle is scheduled to return to Earth on Saturday, November 29, landing at NASA's Kennedy Space Center in Florida, and bringing to an end its 22nd mission, the 27th shuttle flight to the International Space Station and the 124th flight in shuttle program history. Endeavour is commanded by veteran space flier Commander Chris Ferguson, pictured in the center. Other crew members, pictured from left to right, are Mission Specialists Sandra Magnus, Steve Bowen and Donald Pettit, Pilot Eric Boe, Mission Specialists Shane Kimbrough and Heidemarie Stefanyshyn-Piper. Image: NASA

The launch of HepaLife's patented PICM-19 cells aboard the Space Shuttle Endeavour marks the Company's first-ever participation in space flight microgravity experiments. To-date, HepaLife has acquired and developed its cell-based technologies as part of the Company's efforts to develop the first-of-its-kind bioartificial liver device intended for the treatment of liver failure.

Recently, HepaLife announced completion of its acquisition of a novel liver support technology with important fast-track and orphan drug designations by the United States Food and Drug Administration, tested in America's largest-ever human clinical trial for bioartificial liver assist devices. HepaLife significantly enhanced its cell-line supported bioartificial technology, bolstered the Company's intellectual property portfolio, and substantially cut its time-to-market for a commercial bioartificial liver device.

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based medical technologies addressing prevalent human health concerns.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

http://www.hepalife.com

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.